Abstract
The African trypanosome, Trypanosoma brucei, is a protozoan that causes sleeping sickness in humans and Ngana in livestock. These flagellated parasites are directly exposed to immune defences as they circulate in the mammalian host bloodstream but they maintain persistent infections by undergoing antigenic variation. Central to this process is mono-allelic transcription and switching of the expressed variant-surface glycoprotein (VSG) gene which encodes the vast majority of their dense surface coat. The active telomeric VSG is transcribed by RNA polymerase I in an ‘expression site body’ (ESB) while transcription attenuation occurs at ‘inactive’ telomeres. Here, I review what is known about the molecular mechanisms involved in achieving antigenic variation and outline how we intend to exploit genome sequence and new tools, particularly RNA interference, to identify and characterise factors required for VSG regulation.
Keywords: antigenic variation, genome, rnai, trypanosoma brucei, vsg
Current Molecular Medicine
Title: The Molecular Control of Antigenic Variation in Trypanosoma brucei
Volume: 4 Issue: 6
Author(s): David Horn
Affiliation:
Keywords: antigenic variation, genome, rnai, trypanosoma brucei, vsg
Abstract: The African trypanosome, Trypanosoma brucei, is a protozoan that causes sleeping sickness in humans and Ngana in livestock. These flagellated parasites are directly exposed to immune defences as they circulate in the mammalian host bloodstream but they maintain persistent infections by undergoing antigenic variation. Central to this process is mono-allelic transcription and switching of the expressed variant-surface glycoprotein (VSG) gene which encodes the vast majority of their dense surface coat. The active telomeric VSG is transcribed by RNA polymerase I in an ‘expression site body’ (ESB) while transcription attenuation occurs at ‘inactive’ telomeres. Here, I review what is known about the molecular mechanisms involved in achieving antigenic variation and outline how we intend to exploit genome sequence and new tools, particularly RNA interference, to identify and characterise factors required for VSG regulation.
Export Options
About this article
Cite this article as:
Horn David, The Molecular Control of Antigenic Variation in Trypanosoma brucei, Current Molecular Medicine 2004; 4 (6) . https://dx.doi.org/10.2174/1566524043360078
DOI https://dx.doi.org/10.2174/1566524043360078 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Polymeric Invasive and Non-Invasive Nanocarriers Assisted
Transdermal Drug Delivery for Improved Penetration and Bioavailability
Drug Delivery Letters Celastrol and Terpenes as Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry The Ubiquitin-Dependent Proteolytic System and other Potential Targets for the Modulation of Nuclear Factor-kB (NF-kB)
Current Drug Targets Pharmacogenetics in Treatment of Rheumatoid Arthritis
Current Pharmaceutical Design Revealing the Synergistic Mechanism of Multiple Components in Compound Fengshiding Capsule for Rheumatoid Arthritis Therapeutics by Network Pharmacology
Current Molecular Medicine Involvement of Coagulation and Hemostasis in Inflammatory Bowel Diseases
Current Vascular Pharmacology Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone Turnover: An Evidence-Based Review
Reviews on Recent Clinical Trials Preface (Hot Topic: New Frontiers and ”Pitfalls“ in Cytokine and Anti-cytokine Therapies Executive Editor: Atsushi Oda)
Current Pharmaceutical Design Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Editorial (Thematic Issue: Medical Challanges in Inflammatory Bowel Disease: Quo Vadis in Disease Complexity?)
Current Drug Targets The Detection of Anti-adalimumab Antibodies in a Series of Inflammatory Polyarthritis: three ELISA Methods Compared
Drug Metabolism Letters The Use of Growth Factors in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design subject Index To Volume 1
Current Molecular Medicine Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design Disease Modifying Approaches for Alzheimers Pathology
Current Pharmaceutical Design